News

Capestart

Cambridge, MA, August 25, 2025—CapeStart, an AI solutions and services firm, announced that its CapeStart MadeAi™ GenAI Platform for Life Science Content Synthesis was a winner of a Stevie® Award in The 22nd Annual International Business Awards® today—an award that CapeStart also secured in 2024 with an earlier version of MadeAi.

Capestart

CAMBRIDGE, MA, USA and NAGERCOIL, INDIA August 11, 2025—CapeStart, Inc. , an AI solutions and services firm headquartered in Cambridge, MA, is expanding its AI Center of Excellence by opening an office in Chennai, India to continue to attract talented, innovative generative AI (GenAI) professionals.

Pharmaceutical Executive

Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.

Drug Discovery & Development

Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development speed.

Business Wire

At today’s ISPOR Montreal 2025 Conference, CapeStart, Inc. announced a major new release of MadeAi™—its award-winning generative AI-based platform that expedites the synthesis of content and data for the life sciences, helping time-strapped teams to scale faster, strengthen regulatory submissions, and advance the pace of scientific research.

pharmaphorum

GenAI can help with JCA submissions tremendously. With seven years of experience in which numerous large pharma companies and CROs have deployed AI solutions in production, GenAI has demonstrated it can facilitate tedious, time-consuming processes in need of thoughtful, highly skilled oversight.